Back to results
US 2026/0265797 A1Published application
Conversion of homofarnesol to ambroxide
AssigneeConagen Inc.
InventorsCody Ryan Lemke, Yisheng Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, at least in part, to the production of ambroxide or a derivative thereof from homofarnesol. The production can be mediated in a cellular system (e.g., an Escherichia coli bacterium) or in an enzymatic reaction mixture without a cellular system.
Claims25
A process of producing ambroxide or an ambroxide derivative from homofarnesol, comprising use of:
- a. a polypeptide with the sequence of SEQ ID NOs.:
- 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, or 39;
- b. a polypeptide with a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NOs.:
- 3, 37, or 39;
- or
- c. a chimeric polypeptide, such as a circular permutant, comprising a functional fragment or domain of a polypeptide with the sequence of SEQ ID NOs.:
- 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35.
4 more elements
-19. (canceled)
-27. (canceled)
(canceled)
-32. (canceled)
-35. (canceled)
Dependencies are inferred from the claim text.